Shots:

• The first patient has been dosed in P-Ib trial evaluating SpringWorks’ Nirogacestat (GSI) + Janssen’s Teclistamab (Ab targeting BCMA and CD3) in patients with r/r MM. Janssen assumes all costs of study & other expenses related to the supply of nirogacestat
• In preclinical models- Nirogacestat increased the cell surface density of BCMA- reduced the levels of soluble BCMA and enhanced the activity of BCMA-targeted therapies
• SpringWorks has formed a joint oversight committee with Janssen to manage study results- regulatory and other activities and is currently conducting a global P-III DeFi trial assessing nirogacestat vs PBO in adults with progressing desmoid tumors

  Ref: GlobeNewswire | Image: Janssen